DongKook Pharmaceutical Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	49,664	50,272	60,552	73,693	85,444	54,537
Short-Term Investments	61,661	40,582	33,608	29,512	83,439	120,425
Trading Asset Securities	4,566	-	-	3,899	1,047	1,329
Cash & Short-Term Investments	115,891	90,854	94,160	107,105	169,929	176,291
Cash Growth	29.33%	-3.51%	-12.09%	-36.97%	-3.61%	13.96%
Accounts Receivable	214,409	180,595	161,107	134,072	123,949	122,675
Other Receivables	21,872	22,000	17,779	17,361	14,046	12,745
Receivables	243,000	209,389	179,061	151,600	139,299	136,983
Inventory	178,076	159,577	138,343	120,152	102,591	79,048
Prepaid Expenses	5,734	4,639	4,058	2,629	3,949	1,723
Other Current Assets	5,646	5,547	3,575	3,836	4,457	4,717
Total Current Assets	548,347	470,007	419,197	385,321	420,226	398,763
Property, Plant & Equipment	307,535	299,459	272,705	263,355	234,941	194,967
Long-Term Investments	118,135	119,662	108,300	87,892	71,363	47,375
Goodwill	12,172	12,172	-	-	-	-
Other Intangible Assets	19,325	19,733	8,537	8,202	6,916	7,299
Long-Term Accounts Receivable	-	-0	-	-	-	-
Long-Term Deferred Tax Assets	2,320	1,892	1,702	1,695	1,970	1,944
Long-Term Deferred Charges	11,512	10,594	7,626	2,672	-	-
Other Long-Term Assets	17,959	19,646	15,466	13,191	8,655	6,816
Total Assets	1,037,318	953,165	839,535	768,330	750,076	663,165
Accounts Payable	101,942	80,351	62,069	33,405	29,171	26,523
Accrued Expenses	5,189	4,212	3,624	2,754	3,603	2,087
Short-Term Debt	29,544	46,744	48,228	36,954	82,191	13,854
Current Portion of Long-Term Debt	21,047	2,227	5,729	-	-	-
Current Portion of Leases	2,697	3,089	2,528	1,954	2,044	2,557
Current Income Taxes Payable	11,181	14,085	4,949	10,293	6,758	11,891
Current Unearned Revenue	96.98	416.12	0.95	0.86	0.78	0.84
Other Current Liabilities	91,384	81,568	75,982	88,153	96,501	88,053
Total Current Liabilities	263,080	232,692	203,111	173,514	220,269	144,966
Long-Term Debt	15,786	22,904	18,750	25,000	10,000	49,000
Long-Term Leases	4,023	5,723	1,469	2,449	3,687	3,115
Pension & Post-Retirement Benefits	-	-	-	-	-	454.15
Long-Term Deferred Tax Liabilities	3,813	6,505	4,846	4,806	5,765	3,288
Other Long-Term Liabilities	7,215	6,364	7,144	6,471	6,378	6,607
Total Liabilities	293,918	274,189	235,319	212,241	246,099	207,431
Common Stock	22,442	22,230	22,230	22,230	22,230	22,230
Additional Paid-In Capital	23,141	24,800	16,944	14,371	14,459	14,293
Retained Earnings	601,358	558,208	507,318	467,179	419,761	376,729
Treasury Stock	-3,016	-3,016	-3,053	-3,095	-3,138	-3,138
Comprehensive Income & Other	869.51	869.51	869.51	869.51	869.51	869.51
Total Common Equity	644,795	603,092	544,309	501,554	454,181	410,983
Minority Interest	98,432	75,499	31,480	29,125	27,079	24,438
Shareholders' Equity	743,400	678,976	604,216	556,089	503,977	455,734
Total Liabilities & Equity	1,037,318	953,165	839,535	768,330	750,076	663,165
Total Debt	73,098	80,687	76,704	66,357	97,922	68,526
Net Cash (Debt)	42,793	10,167	17,456	40,748	72,008	107,765
Net Cash Growth	198.13%	-41.76%	-57.16%	-43.41%	-33.18%	14.14%
Net Cash Per Share	956.52	227.26	390.25	911.09	1610.23	2409.84
Filing Date Shares Outstanding	44.39	43.97	43.96	43.96	43.95	43.95
Total Common Shares Outstanding	44.39	43.97	43.96	43.96	43.95	43.95
Working Capital	285,267	237,315	216,087	211,807	199,957	253,796
Book Value Per Share	14525.01	13716.51	12381.26	11410.55	10334.43	9351.51
Tangible Book Value	613,299	571,187	535,772	493,352	447,265	403,684
Tangible Book Value Per Share	13815.50	12990.87	12187.07	11223.95	10177.07	9185.42
Land	107,419	114,638	102,959	107,234	91,415	82,086
Buildings	129,684	132,740	114,323	82,855	56,325	52,435
Machinery	257,539	239,876	211,538	172,505	158,211	138,956
Construction In Progress	25,175	9,257	7,535	46,091	57,785	36,871

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.